Advancing Therapies for Chromophobe RCC: KIT as a Gateway for Targeted Drug Delivery
Автор: GU Oncology Now
Загружено: 2025-09-11
Просмотров: 69
Michel Alchoueiry, MD, Associate Scientist at Brigham and Women’s Hospital and Instructor in Medicine at Harvard Medical School, discusses a compelling new preclinical study that positions KIT as a promising therapeutic target in metastatic chromophobe renal cell carcinoma (ChRCC).
The study demonstrates that LOP628, a KIT-directed ADC, selectively reduced viability by roughly 60% in ChRCC-derived cell lines—without affecting clear cell RCC models—highlighting its potential specificity and therapeutic window in this rare and treatment-resistant cancer.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: